IBRX Q3 2017 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8,000-33.3% YoY

Gross Profit

$8,000100.0% margin

Operating Income

-$24M-295937.5% margin

Net Income

-$24M-299612.5% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-42.9%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$21M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$278M

Total Liabilities

$40M

Stockholders' Equity

$238M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8,000	$12,000	-33.3%
Gross Profit	$8,000	$12,000	-33.3%
Operating Income	-$24M	-$32M	+25.8%
Net Income	-$24M	-$32M	+24.9%

Geographic Segments

San Diego California

$100,000100%